TScan Therapeutics, Inc. (TCRX) tiene un P/E histórico negativo de -1.0, lo que significa que la empresa actualmente no es rentable en base a los últimos doce meses (TTM). El rendimiento de ganancias histórico es -95.26%.
Criterios demostrados por esta página:
Puntuación General SharesGrow: 52/100 con 2/7 criterios aprobados.
| Year | P/E (TTM) | Ratio PEG | Ratio P/B | Ratio P/S | Rendimiento por Dividendo |
|---|---|---|---|---|---|
| 2019 | -19.2 | 0.00 | 6.16 | 0.00 | - |
| 2020 | -10.0 | -0.10 | -6.17 | 241.34 | - |
| 2021 | -2.2 | -0.02 | 0.67 | 10.61 | - |
| 2022 | -0.6 | -0.02 | 0.37 | 2.75 | - |
| 2023 | -4.3 | 0.09 | 2.53 | 18.17 | - |
| 2024 | -2.7 | 0.17 | 1.41 | 120.90 | - |
| 2025 | -1.0 | 0.08 | 1.05 | 12.58 | - |
| Year | EPS (Diluido) | Ingresos | Ingreso Neto | Margen Neto |
|---|---|---|---|---|
| 2019 | $-0.53 | $0.00 | $-13.11M | - |
| 2020 | $-1.04 | $1.09M | $-26.02M | -2398.2% |
| 2021 | $-2.03 | $10.14M | $-48.63M | -479.5% |
| 2022 | $-2.74 | $13.54M | $-65.81M | -486.2% |
| 2023 | $-1.36 | $21.05M | $-89.22M | -423.9% |
| 2024 | $-1.14 | $2.82M | $-127.5M | -4527.7% |
| 2025 | $-1.00 | $10.33M | $-129.77M | -1256.8% |
| Year | EPS (Prom.) | Rango EPS | Ingresos (Prom.) | Rango de Ingresos | Analistas |
|---|---|---|---|---|---|
| 2026 | $-0.93 | $-1.60 – $-0.62 | $8.47M | $2.72M – $11.8M | 4 |
| 2027 | $-0.87 | $-1.14 – $-0.66 | $8.12M | $7.67M – $8.56M | 4 |
| 2028 | $-0.81 | $-1.04 – $-0.64 | $26.56M | $14.93M – $32.47M | 3 |
| 2029 | $-0.60 | $-0.78 – $-0.26 | $49.02M | $27.56M – $59.94M | 1 |
| 2030 | $-0.36 | $-0.46 – $-0.16 | $85.82M | $48.24M – $104.93M | 1 |
